VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data to be Presented During an Oral Presentation at the 2023 American College of Cardiology’s Annual Scientific Sessions Meeting BOSTON, March 03, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., […]